MUDr. Eva Dokoupilová, MBA - životopis

Fojtík, Z., Řehák, Z., Šimíková, J., Kielkowská, I., Dokoupilová, E. Non-invasive imaging in the diagnosis of large vessel vasculitis. Scand. J. Rheumatol., 2006, vol. 35, supl. 121, p. 52.

Distler, O., Eich, W., Dokoupilova, E., Dvorak, Z., Fleck, M., Gaubitz, M., Hechler, M., Jansen, J.P., Krause, A., Bendszus, M., Pache, L., Reiter, R., Müller-Ladner, U. Evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: results of a twelve-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis and Rheumatism. 2010, vol. 62, no. 1, p. 291–300.

Branco, J.C., Zachrisson, O., Perrot, S., Mainguy, Y.; Multinational Coordinator Study Group, Collaborators: Klanova, I., Polivka, J., Svoboda, P., Dokoupilova, E., Danneskiold-Samsoe, B., Hannonen, .P, Kouri, J.P., Lehtonen-Veromaa, M., Partinen, M., Auvinet, B., Baron, D., Cherin, P., Courtheoux, F., Delorme, C., Dumolard, A., Picard, P., Hatron, P.Y., Lanteri-Minet, M., Maugars, Y., Mejjad, O., Schalck, R., Rioult, B., Roussel, P., Serra, E., Viel, E., Mazieres, B., Ginies, P., Cantagrel, N., De Korwin, J.D., Ginesty, E., Nadstawek, J., Neeck, G., Späth, M., Alten, R., Bolten, W., Bianchi, G., Biasi, G., Bombardieri, S., Cazzola, M., Cimmino, M.A., Fantini, F., Punzi, L., Venditti, C., Trotta, F., Matucci Cerinic, M., Grassi, W., Ofjord, S., Knudsrod, O., Szczepanski, L., Targonska-Stepniak, B., Szechiński, J., Araujo, D., Figueiredo, G., Tavares, V., Paiva, T., Cruz, M., Bolosiu, H., Codreanu, C., Ionescu, R., Radulescu, F., Suta, M., Collado, A., Alegre, C., Rivera, J., Rodriguez de la Serna, A., Riestra, J.L., Vidal, J., De Teresa, L., Petersson, I., Bragee, B., Sörensen, J., Walker, D. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. The Journal of Rheumatology. 2010, vol. 37, no. 4, p. 851–859.

Dokoupilova, E. Úspěch biologické léčby u revmatoidní artritidy. Medical Tribune. 2011, vol. 7, no. 8, 2 p.

Durez, P., Genovese, C. G., Richards, H. B., Supronik, J., Dokoupilova, E., Aelion, J. A., Lee, S.-H., Codding, C. E., Kellner, H., Ikawa, T., Hugot, S., Ligozio, G. and Mpofu, S. Secukinumab Treatment Provides Sustained Response Over One Year in Patients with Rheumatoid Arthritis. Congress Rheumatology 2012.

Genovese, M. C., Durez, P., Richards, H. B., Supronik, J., Dokoupilova, E., Mazurov, V., Aelion, J. A., Lee, S.-H., Codding, C. E., Kellner, H., Ikawa, T., Hugot, S., Mpofu, S., FRCP. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody in patients with rheumatoid arthritis: A phase II, dose-finding, double-blind, randomized, placebo-controlled study. Annals of the Rheumatic Diseases. 2012.

Genovese, M.C., Durez, P., Richards, H.B., Supronik, J., Dokoupilova, E., Mazurov, V., Aelion, J.A., Lee, S.H., Codding, C.E., Kellner, H., Ikawa, T., Hugot, S., Mpofu, S. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study.Annals of the Rheumatic Diseases [online]. 2013, 72(6), 863-869.

Genovese, M.C., Durez, P., Richards, H.B., Supronik, J., Dokoupilova, E., Aelion, J.A., Lee, S.H., Codding, C.E., Kellner, H.,Ikawa, T., Hugot, S., Ligozio, G., Mpofu, S. One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study. The Journal of Rheumatology [online]. 2014, 41(3), 414-421.

Šenolt, L., Leszyzynski, P., Dokoupilova, E.,, Göthberg, M., Valencia, X., Hansen, B. B., Caete, J. D. Efficacy and Safety of Anti-Interleukin-20 Monoclonal Antibody in Patients With Rheumatoid Arthritis: A Randomized Phase IIa Trial. Arthritis & Rheumatology [online]. 2015, 67(6), 1438-1448.

Choe, Jung-Yoon, Nenad Prodanovic, Jaroslaw Niebrzydowski, et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Annals of the Rheumatic Diseases [online]. 2016, 76(1), 58-64.

Damjanov, Nemanja, Sarolta Karpati, Lajos Kemeny, et al. Efficacy and safety of etanercept in psoriasis and psoriatic arthritis in the PRESTA study: analysis in patients from Central and Eastern Europe. Journal of Dermatological Treatment [online]. 2017, 29(1), 8-12.

Weinblatt, Michael E., Asta Baranauskaite, Jaroslaw Niebrzydowski, et al. Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis. Arthritis & Rheumatology [online]. 2018, 70(1), 40-48.

Pavelka, Karel, Alan Kivitz, Eva Dokoupilova, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Research & Therapy [online]. 2017, 19(1).

Smolen, Josef S., Jung-Yoon Choe, Nenad Prodanovic, et al. Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results. Rheumatology [online]. 2017, 56(10), 1771-1779.

Langdahl, Bente L, Cesar Libanati, Daria B Crittenden, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. The Lancet[online]. 2017, 390(10102), 1585-1594.

Blanco, Francisco J., Rüdiger Möricke, Eva Dokoupilova, Christine Codding, Jeffrey Neal, Mats Andersson, Susanne Rohrer A Hanno Richards. Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study. Arthritis & Rheumatology [online]. 2017, 69(6), 1144-1153.

Smolen, Josef S, Jung-Yoon Choe, Nenad Prodanovic, et al. Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study. Annals of the Rheumatic Diseases [online]. 2018, 77(2), 234-240.

Dokoupilová, E., J Aelion, T Takeuchi, N Malavolta, Pp Sfikakis, Y Wang, S Rohrer A Hb Richards. Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritis. Scandinavian Journal of Rheumatology [online]. 2018, , 1-6.

Weinblatt, Michael E., Asta Baranauskaite, Eva Dokoupilova, et al. Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis. Arthritis & Rheumatology [online]. 2018, 70(6), 832-840.

Nash, Peter, Philip J. Mease, Iain B. Mcinnes, et al. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Research & Therapy [online]. 2018, 20(1).

Kivitz, Alan J., Ulf Wagner, Eva Dokoupilova, Jerzy Supronik, Ruvie Martin, Zsolt Talloczy, Hanno B. Richards A Brian Porter. Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study. Rheumatology and Therapy [online]. 2018, 5(2), 447-462.

Sudha Visvanathan, Stefan Daniluk, Rafał Ptaszyński, Ulf Müller Ladner, Meera Ramanujam, Bernd Rosenstock, Anastasia G Eleftheraki, Richard Vinisko, Alena Petříková, Herbert Kellner, Eva Dokoupilova, Brdygida Kwiatkowska, Rie e Alten, Christian Schwabe, Patrick Baum, David Joseph, Jay S Fine, Steven J Padula, Jȕrgen Steffgen. Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study Annals of the Rheumatic Diseases. Jun 2019, 78 (6) 754-760.

Deodhar A, van der Heijde D, Gensler LS, Kim TH, Maksymowych WP, Østergaard M, Poddubnyy D, Marzo-Ortega H, Bessette L, Tomita T, Leung A, Hojnik M, Gallo G, Li X, Adams D, Carlier H, Sieper J; COAST-X Study Group, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet. 2020 Jan 4;395(10217):53-64.

Mark C. Genovese, Josephine Glover, Maria Greenwald, Wieslawa Porawska, Elias Chalouhi El Khouri, Eva Dokoupilova, Juan Ignacio Vargas, Mykola Stanislavchuk, Herbert Kellner, Elena Baranova, Nobuhito Matsunaga and Rieke Alten. FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension. Arthritis Research & Therapy 2019, 21:281.

Karel Pavelka, Alan J. Kivitz, Eva Dokoupilova, Ricardo Blanco, Marco Maradiaga, Hasan Tahir, Yi Wang, Brian O. Porter, Anna Stefanska, Hanno B. Richards, and Susanne Rohrer, on behalf of the MEASURE 3 study group. Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study. ACR Open Rheumatology Vol. 0, No. 0, Month 2020, pp 1–9.

Karel Pavelka, Andrea Bernetti, Nicola Giordan, Eva Dokoupilová, Valter Santilli. Dose-response of hyaluronate-based viscoelastic hydrogels for the treatment of knee osteoarthrosis: a prospective, randomized, comparative clinical trial. Minerva Ortopedica e Traumatologica. 2020 June;71(2):45-55.

Pelletier JP, Raynauld JP, Dorais M, et al. An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis. Rheumatology (Oxford). 2020;59(12):3858-3868.

Wiland P, Jeka S, Dokoupilová E, et al. Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study. BioDrugs. 2020;34(6):809-823.

Deodhar A, Blanco R, Dokoupilová E, et al. Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study. Arthritis Rheumatol. 2021;73(1):110-120.

Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2 [published online ahead of print, 2020 Dec 3]. Ann Rheum Dis. 2020;80(3):312-320.

Orbai AM, Gratacós J, Turkiewicz A, et al. Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2). Rheumatol Ther. 2021;8(1):199-217.

Mease PJ, Lertratanakul A, Papp KA, et al. Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study. Rheumatol Ther. 2021;8(2):903-919.

Fojtík, Z., Řehák, Z., Šimíková, J., Kielkowská, I., Dokoupilová, E. Non-invasive imaging in the diagnosis and management on large vessel vasculitis. In 6 th Central European Congress of Rheumatology, Bled, May 4th-6th, 2006, poster no. 102. Zdravniški vestnik, 2006, vol. 75, suppl. 1, p.I-10.

Senolt, L., Gothberg, M., Valencia, X., Dokoupilova, E.; Clinical Responses and Patient Reported Outcomes to NNC0109-0012 (anti-IL-20 mAb) in RheumatoidArthritis (RA) Patients Following 12-Weeks Dosing and 13 Weeks Follow up: Results From a Phase 2a Trial. [abstract]. Arthritis Rheum 2012;64 Suppl 10:836

Senolt, L., Hansen, B. B., Strandberg-Larsen, M., Dokoupilova, E. PMS2 Improvements in Physical Function and Disability in Patients With Rheumatoid Arthritis After Treatment With NNC0109-0012 (Anti-IL-20 mAb) in a Phase 2A Trial. Value in Health[online]. 2012, 15(7), A439

Dokoupilova, E., Jeka, S., Vencovsky, J., Badurski, J., Prins, K., Strand, V., et al; Use Of a Biologic Marker For An Integrated Pharmacodynamic and Clinical Analysis To Inform Further Clinical Development, Including Dose Selection For The Phase 2b Trial - Treat 2b - Of Tregalizumab In Rheumatoid Arthritis. [abstract]. Arthritis Rheum 2013;65 Suppl 10 :1412

Pavelka, K., Hejduk, K. Mann, H., Dokoupilova, E. a Suchy D. AB0317 Swollen joints- the only predictor of achieving low disease activity in ra with tocilizumab therapy in czech national registry attra. Annals of the Rheumatic Diseases [online]. 2014, 72(Suppl 3), A884-A884

Weinblatt, M.E., Baranauskaite, A., Niebrzydowski, J., Dokoupilova, E., Zielinska, A., Sitek-Ziolkowska, K., Jaworski, J., Racewicz, A., Pileckyte, M., Jedrychowicz-Rosiak, K., Zhdan, V., Cheong, S.Y., Ghil, J.: A Phase III, Randomized, Double-Blind Clinical Study Comparing SB5, an Adalimumab Biosimilar, with Adalimumab Reference Product (Humira (R)) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (24-week Results). Arthritis Rheum. 2015; 67 Suppl. 10: 8L.

Choe, J.Y., Prodanovic, N., Niebrzydowski, J.. Staykov, I., Dokoupilova E., Baranauskaite, A., Yatsyshyn, R., Mekic, M., Porawska, W., Ciferska, H., Jedrychowicz-Rosiak, K., Zielinska, A., Choi, J., Rho, Y.H., Smolen, J.S.: A Randomized, Double-Blind, Phase III Study Comparing SB2, an Infliximab Biosimilar, to the Infliximab Reference Product (Remicade (R)) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy: 54-Week Results. Arthritis Rheum. 2015; 67 Suppl. 10: 2056.

Weinblatt ME, Baranauskaite A, Niebrzydowski J, Dokoupilova E, Zielinska A, Sitek-Ziolkowska K, Jaworski J, Racewicz A, Pileckyte M, Jedrychowicz-Rosiak K, Zhdan V, Cheong SY, Ghil J. A Phase III, Randomized, Double-Blind Clinical Study Comparing SB5, an Adalimumab Biosimilar, with Adalimumab Reference Product (Humira®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (24-week Results) [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10).

Rahman, P., V. Strand, I.B. Mcinnes, Et al. Secukinumab Improves Physical Function, Quality of Life, Fatigue and Work Productivity in Patients with Active Psoriatic Arthritis in Future 2, A Phase 3 Trial. Annals of the Rheumatic Diseases [online]. 2015, 74(Suppl 2), 356-356

Strand V., Rahman, P., Churchill M., Dokoupilova E., Marzo-Orteg H., McInnes I.B., Zuazo, J., Mpofu S., Pricop L.: Secukinumab provides sustained improvement in physical function, health-related quality of life, fatigue, and work productivity in patients with active psoriatic arthritis: 52-week results from an international phase 3 trial. JCR-Journal of clinical Rheumatology. 2016; 22, 3: 142-143.

Malouf, J., Langdahl B., Libanati C., Crittenden D. B., Bolognese M. A., Brown J. P., Daizadeh N. S., Dokoupilova E., Engelke K., Finkelstein J.S., Genant H. K., Goemaere S., Hyldstrup L., Jodar-Gimeno E., Keaveny T. M., Kendler D., Lakatos, P., Maddox J., Massari, F. E., Molina J. F., Ulla M. R., Grauer A.: Superior gains in bone mineral density and estimated strength at the hip for romosozumab compared with teriparatide in women with postmenopausal osteoporosis transitioning from bisphosphonate therapy: results of the phase 3 open-label structure study. Osteoporosis International. 2016; 27, 1: S40-S41. (konference: WCO-IOF-ESCEO World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, Malaga, Španělsko)

Smolen, J.S., J.-Y. Choe, N. Prodanovic, et al. Comparable Safety and Immunogenicity and Sustained Efficacy after Transition To SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product in Patients with Rheumatoid Arthritis: Results of Phase III Transition Study. Annals of the Rheumatic Diseases [online]. 2016, 75(Suppl 2), 488.1-488. (EULAR 2016)

Daniluk, S., R. Ptaszynski, U. Mueller-Ladner, et al. Safety and Efficacy of BI 655064, An Antagonistic Anti-CD40 Antibody in Rheumatoid Arthritis (RA) Patients: Table 1. Annals of the Rheumatic Diseases [online]. 2016, 75(Suppl 2), 718.1-718 (EULAR 2016)

Langdahl, B., C. Libanati, D. Crittenden, et al. Superior Gains in Bone Mineral Density and Estimated Strength at The Hip for Romosozumab Compared with Teriparatide in Women with Postmenopausal Osteoporosis Transitioning from Bisphosphonate Therapy: Results of The Phase 3 Open-Label Structure Study. Annals of the Rheumatic Diseases [online]. 2016, 75(Suppl 2), 92.2-93 (EULAR 2016)

Weinblatt, M., A. Baranauskaite, J. Niebrzydowski, et al. Sustained Efficacy and Comparable Safety and Immunogenicity after Transition To SB5 (An Adalimumab Biosimilar) vs Continuation of The Adalimumab Reference Product in Patients with Rheumatoid Arthritis: Result of Phase III Study. Annals of the Rheumatic Diseases [online]. 2016, 75(Suppl 2), 487.2-487 (EULAR 2016)

Pavelka, K., Kivitz, AJ., Dokoupilova, E., Blanco, R.,Maradiaga, M.,Tahir, H., Slade, A., Wang, Y., Rohrer, S., Porter, B.: Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Results from a Phase 3 Study Arthritis Rheum. 2017; 69 Suppl. 10: 1828.

Alten, R., V. Tseluyko, T. Hala, Et Al. Efficacy, Safety And Immunogenicity From Week 30 To Week 54 In a randomised, double-blind phase iii study comparing a proposed infliximab biosimilar (PF-06438179/GP1111) with reference infliximab. Annals of the Rheumatic Diseases 77, supplement Suppl, year 2018, page A612 (EULAR 2018)

Kivitz AJ, Pavelka K, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, Wang Y, Porter B, Stefanska A, Rohrer S, Richards H. Sustained Improvements in Signs and Symptoms of Active Ankylosing Spondylitis and Reassuring Safety with Secukinumab 300mg: 3-Year Results from a Phase 3 Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). (ACR 2018).

Wiland P, Jeka S, Dokoupilová E, Miranda Limón JM, Jauch-Lembach J, Thakur A, Haliduola H, Gaylis NB. A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Efficacy, Safety and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). (ACR 2018).

Piotr Wiland, Sławomir Jeka, Eva Dokoupilova, Juan Manuel Miranda Limon, Julia Jauch-Lembach, Anjali Thakur, Halimuniyazi Haliduola, Norman Gaylis. Efficacy, safety, and immunogenicity results of the switch from reference adalimumab (refadl) to sandoz biosimilar adalimumab (GP2017, sdz-adl) from admyra phase 3 study in patients with moderate-to-severe rheumatoid arthritis (RA). Ann Rheum Dis, volume 78, supplement 2, 2019, page A706 (EULAR 2019).

Deodhar A, Blanco R, Dokoupilova E, van de Sande M, Hall S, Wiksten A, Porter B, Richards H, Haemmerle S, Braun J. Secukinumab 150 mg Significantly Improved Signs and Symptoms of Non-radiographic Axial Spondyloarthritis: Results from a Phase 3 Double-blind, Randomized, Placebo-controlled Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). (ACR 2019).

Behrens F, Sewerin P, de Miguel E, Patel Y, Batalov A, Dokoupilova E, Kleinmond C, Pournara E, Shekhawat A, Jentzsch C, Wiedon A, Baraliakos X. Achilles Tendon Enthesitis and Disease Burden in Psoriatic Arthritis and Axial Spondyloarthritis: Baseline Results from a Randomized Controlled Trial [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). (ACR 2019).

A Deodhar, R Blanco, E Dokoupilova, M van de Sande, S Hall, A Wiksten, BO Porter, HB Richards, S Haemmerle, J Braun. Secukinumab 150 mg Significantly Improved Signs and Symptoms of Nonradiographic Axial Spondyloarthritis: Results from a Phase 3, Double-Blind, Randomized, Placebo-Controlled Study. Poster presented at the Phoenix Rheumatology Association (PRA) Rheumatology Update: Highlights From ACR 2019; January 18, 2020.

Behrens F, Sewerin P, De Miguel E, Patel Y, Batalov A, Dokoupilova E, Kleinmond C, Pournara E, Shekhawat A, Jentzsch C, Wiedon A, Baraliakos X. Efficacy and Safety of Secukinumab in Patients with Spondyloarthritis and Enthesitis at the Achilles Tendon: 52-weeks Results from a Randomized, Placebo-controlled Phase 3b Trial [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). (ACR 2020).

Genovese M, Lertratanakul A, Anderson J, Papp K, Tillett W, Van den Bosch F, Tsuji S, Dokoupilova E, Keiserman M, Wang X, Zhong S, Zueger P, Pangan A, Mease P. Efficacy and Safety of Upadacitinib in Patients with Active Psoriatic Arthritis and Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). (ACR 2020).

Gratacós J, Turkiewicz A, Dokoupilova E, Gellett A, Sprabery A, Geneus V, Constantin A. Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3 Year Results from a Phase 3 Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). (ACR 2020).

D. Poddubnyy, A. Deodhar, X. Baraliakos, R. Blanco, E. Dokoupilova, S. Hall, A. Kivitz, M. G. H. Van de Sande, A. Stefanska, P. Pertel, H. Richards, J. Braun. Secukinumab 150 mg provides sustained improvement in signs and symptoms of non-radiographic axial spondyloarthritis: 2-year results from the prevent study. Ann Rheum Dis, volume 80, supplement 1, year 2021, page 707. (EULAR 2021).

P. J. Mease, A. Lertratanakul, K. Papp, F. Van den Bosch, S. Tsuji, E. Dokoupilova, M. Keiserman, X. Bu, L. Chen, R. Mccaskill, P. Zueger, E. Mcdearmon-Blondell, A. Pangan, W. Tillett. Upadacitinib in patients with psoriatic arthritis refractory to biologic disease-modifying antirheumatic drugs: 56-week data from the phase 3 select-psa 2 study. Ann Rheum Dis, volume 80, supplement 1, year 2021, page 312. (EULAR 2021)